Myovant Sciences (NYSE: MYOV) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Myovant Sciences to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

79.2% of Myovant Sciences shares are held by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.8% of Myovant Sciences shares are held by insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Myovant Sciences has a beta of -2.42, indicating that its stock price is 342% less volatile than the S&P 500. Comparatively, Myovant Sciences’ peers have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.

Earnings and Valuation

This table compares Myovant Sciences and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Myovant Sciences N/A -$83.44 million -8.89
Myovant Sciences Competitors $564.12 million $96.17 million 43.60

Myovant Sciences’ peers have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Myovant Sciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -53.75% -48.90%
Myovant Sciences Competitors -13,603.82% -109.96% -27.55%

Analyst Ratings

This is a breakdown of current ratings for Myovant Sciences and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 4 0 3.00
Myovant Sciences Competitors 137 801 1756 59 2.63

Myovant Sciences presently has a consensus price target of $22.50, suggesting a potential upside of 79.57%. As a group, “Biopharmaceuticals” companies have a potential upside of 15.03%. Given Myovant Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Myovant Sciences is more favorable than its peers.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with's FREE daily email newsletter.